Centessa Pharmaceuticals PLC ADR Cash Flow Conversion Efficiency
Centessa Pharmaceuticals PLC ADR cash flow conversion efficiency. Based on the latest financial reports, Centessa Pharmaceuticals PLC ADR (CNTA) has a cash flow conversion efficiency ratio of -0.148x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-72.22 Million) by net assets ($487.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Centessa Pharmaceuticals PLC ADR (2019–2025)
Cash flow conversion efficiency of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. This chart illustrates how Centessa Pharmaceuticals PLC ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Centessa Pharmaceuticals PLC ADR share price for real-time trading data and today's change.
Centessa Pharmaceuticals PLC ADR Cash Flow Conversion Ratio Explained
Centessa Pharmaceuticals PLC ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Centessa Pharmaceuticals PLC ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Centessa Pharmaceuticals PLC ADR ranked by their cash flow conversion efficiency. Also see CNTA company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Weichai Power Co. Ltd
F:WI4
|
0.053x |
|
China Aerospace Times Electronics Co Ltd
SHG:600879
|
0.130x |
|
Mango Excellent Media Co Ltd
SHE:300413
|
0.009x |
|
Inner Mongolia MengDian HuaNeng Thermal Power Corp Ltd
SHG:600863
|
0.081x |
|
Nice Ltd ADR
NASDAQ:NICE
|
0.049x |
|
Matador Resources Company
NYSE:MTDR
|
0.150x |
|
DigitalOcean Holdings Inc
NYSE:DOCN
|
-1.997x |
|
First International Bank of Israel Ltd
TA:FIBI
|
-0.043x |
Annual Cash Flow Conversion Efficiency for Centessa Pharmaceuticals PLC ADR (2019–2025)
The table below shows the annual cash flow conversion efficiency of Centessa Pharmaceuticals PLC ADR from 2019 to 2025. Review Centessa Pharmaceuticals PLC ADR leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $526.86 Million | $-193.82 Million | -0.368x | -3.99% |
| 2024-12-31 | $401.55 Million | $-142.06 Million | -0.354x | +47.88% |
| 2023-12-31 | $236.24 Million | $-160.34 Million | -0.679x | -13.77% |
| 2022-12-31 | $336.17 Million | $-200.55 Million | -0.597x | -115.40% |
| 2021-12-31 | $491.55 Million | $-136.14 Million | -0.277x | +91.93% |
| 2020-12-31 | $3.10 Million | $-10.63 Million | -3.431x | -704.88% |
| 2019-12-31 | $13.66 Million | $-5.83 Million | -0.426x | -- |
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as we… Read more